FLT3–ITD and its current role in acute myeloid leukaemia

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones

(2016) Adhra Al-Mawali et al.   Journal of Hematology & Oncology

Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling

(2016) Sausan A. Moharram et al.   Oncotarget

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor

(2016) Nadine Sandhöfer et al.   Scientific Reports

Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations

(2016) Shaina N Porter et al.   eLife

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine

(2015) N Chatain et al.   LEUKEMIA

FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3

(2015) Anar Damdinsuren et al.   LEUKEMIA RESEARCH

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification

(2015) Yi-Yu Ke et al.   Scientific Reports

IDH1andIDH2mutations confer an adverse effect in patients with acute myeloid leukemia lacking theNPM1mutation

(2014) Shunichiro Yamaguchi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Single cell analysis exposes intratumor heterogeneity and suggests that FLT3-ITD is a late event in leukemogenesis

(2014) Roni Shouval et al.   EXPERIMENTAL HEMATOLOGY

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia

(2014) Hanna Janke et al.   PLoS One

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML

(2014) D L Stirewalt et al.   Blood Cancer Journal

The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling

(2013) Julhash U. Kazi et al.   CELLULAR SIGNALLING

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia

(2013) Jung Eun Park et al.   EMBO Molecular Medicine

FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors

(2013) Adam J. Mead et al.   Cell Reports

Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next-Generation Sequencing Data

(2012) David H. Spencer et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia

(2012) A Y H Leung et al.   LEUKEMIA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Long FLT3 internal tandem duplications and reduced PML-RAR  expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

(2010) M. C. Chillon et al.   HAEMATOLOGICA

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia

(2009) S. Meshinchi et al.   CLINICAL CANCER RESEARCH

Mechanisms of resistance to FLT3 inhibitors

(2009) S. Haihua Chu et al.   DRUG RESISTANCE UPDATES